Viking Therapeutics
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Overview
    • Metabolic Disease Programs
      • VK2809 (NASH)
      • VK2735 (Metabolic Disorders)
    • Rare Disease Program
      • VK0214 (X-ALD)
    • Other Pipeline Programs
      • VK5211 (Hip Fracture, Muscle Wasting)
      • VK0612 (Type 2 Diabetes)
      • VK1430 (Hypertriglyceridemia, NASH)
      • EPOR Agonist Program (Anemia)
  • Investors & Media
    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation
  • Contact

    Webcasts

    Investors

    • Overview
    • Stock Information
    • News & Events
      • Press Releases
      • Webcasts
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation

    E-mail Alerts
    •  Upcoming Events
    •  Past Events
    No events to display
    Loading Events...

     

     

    viking therapeutics

    About

    Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

    Contact

    General Information
    Business Development
    ©2024 Viking Therapeutics
    Terms of Use
    Privacy Policy